The boosting effect of minoxidil 0.1% when combined with dutasteride 0.01% and microneedling in the treatment of female pattern hair loss
Background Female pattern hair loss (FPHL) is a disease characterized by progressive hair thinning. Topical minoxidil is an FDA-approved drug for the treatment of androgenetic alopecia. Dutasteride (a 5α-reductase inhibitor) can also be used in a topical form to reduce its systemic side effects. Bot...
Saved in:
Main Authors: | Reham Essam, Heba Selim, Rana Ehab |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2024-01-01
|
Series: | Journal of the Egyptian Women’s Dermatologic Society |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/jewd.jewd_35_23 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Oral Finasteride (5 mg and 2 mg) versus Topical Minoxidil 5% in Female Pattern Hair Loss
by: Eman Hamed El Morsy, et al.
Published: (2025-01-01) -
Low-dose oral minoxidil in a case of short anagen syndrome
by: Divija Sharma, et al.
Published: (2025-12-01) -
Dutasteride nanoemulsion preparation to inhibit 5‐alpha‐hair follicle reductase enzymes in the hair follicle; an ex vivo study
by: Mehri Memar Bashi Aval, et al.
Published: (2023-02-01) -
The Effect Of 0.01% Atropine On Myopia Progression
by: Amber Khalid
Published: (2024-06-01) -
Patterns of noncicatricial alopecia in children: a cross-sectional study
by: Essam Elden M. Mohamed, et al.
Published: (2023-07-01)